Wilbanks Smith & Thomas Asset Management LLC Alkermes Plc. Transaction History

Wilbanks Smith & Thomas Asset Management LLC

$3.54 Billion
Q1 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2018 Feb 08, 2019	SELL	$27.94 - $44.61 $8,354 - $13,338	-299 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$38.6 - $46.12 $11,541 - $13,789	299 New	299 $13,000

Others Institutions Holding ALKS

# of Institutions

346

Shares Held

183M

Call Options Held

209K

Put Options Held

89.4K

Black Rock Inc. New York, NY

29.1M
Shares

$807 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

20M
Shares

$555 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

14.4M
Shares

$398 Million
0.06% of portfolio
Price T Rowe Associates Inc Baltimore, MD

11M
Shares

$305 Million
0.03% of portfolio
State Street Corp Boston, MA

9.22M
Shares

$256 Million
0.01% of portfolio

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.56B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wilbanks Smith & Thomas Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wilbanks Smith & Thomas Asset Management LLC with notifications on news.

Account